Introduction {#cesec10}
============

Acute severe gastrointestinal bleeding is a common cause of death worldwide.[@bib1] Bleeding can occur from the upper or lower gastrointestinal tract, but upper gastrointestinal bleeding is more common. The leading causes are peptic ulcer, oesophageal varices, and malignancy. The case fatality rate is approximately 10% for upper gastrointestinal bleeding and 3% for lower gastrointestinal bleeding.[@bib2], [@bib3] Many patients re-bleed after initial haemostasis and those that do have a four-times increased risk of death.[@bib4] Patients with acute severe gastrointestinal bleeding usually present with haematemesis or melaena. Patients are often haemodynamically unstable and in need of urgent resuscitation. Acute management of gastrointestinal bleeding includes blood product transfusion, medical or endoscopic therapy, and surgery.

Tranexamic acid reduces bleeding by inhibiting blood clot breakdown (fibrinolysis). Tranexamic acid decreases surgical bleeding and reduces death due to bleeding in patients with traumatic and postpartum haemorrhage.[@bib5], [@bib6], [@bib7], [@bib8] A systematic review and meta-analysis of randomised trials of tranexamic acid for upper gastrointestinal bleeding included seven trials with a total of 1654 patients.[@bib9] There was a large reduction in all-cause mortality with tranexamic acid (risk ratio \[RR\] 0·61, 95% CI 0·42--0·89; p=0·01). However, meta-analyses of small trials are prone to publication and other selection biases, and have a low positive predictive value when compared with results from large multicentre trials.[@bib10] Furthermore, even in aggregate, the trials included in the meta-analysis were too small to assess the effect of tranexamic acid on thromboembolic adverse events.[@bib9] Our objective was to quantify the effects of tranexamic acid on death and thromboembolic events in acute gastrointestinal bleeding.

Research in context**Evidence before this study**Before this study a Cochrane systematic review and meta-analysis of randomised trials of tranexamic acid for upper gastrointestinal bleeding included seven trials with a total of 1654 patients. There was a large reduction in mortality with tranexamic acid (pooled risk ratio \[RR\] 0·61, 95% CI 0·42--0·89; p=0·01). However, given the small size of the included trials and the potential for selection and other biases, we considered this evidence to be hypothesis generating, requiring confirmation in larger trials. Furthermore, there was substantial uncertainty about the risk of thromboembolic events with tranexamic acid (pooled RR 1·86, 95% CI 0·66--5·24).**Added value of this study**The HALT-IT trial included 12 009 patients from 164 hospitals in 15 countries. Adult patients with significant upper or lower gastrointestinal bleeding were randomly assigned to receive tranexamic acid (1 g loading dose followed by 3 g maintenance dose over 24 h) or matching placebo. Tranexamic acid did not reduce death from gastrointestinal bleeding (RR 0·99, 95% CI 0·82--1·18) but was associated with an increased risk of venous thromboembolic events (1·85, 1·15--2·98) and seizures (1·73, 1·03--2·93).**Implications of all the available evidence**The most recent update of the Cochrane review included eight small randomised trials with 1701 participants and showed a reduction in mortality with tranexamic acid (RR 0·60, 95% CI 0·42--0·87). Although we cannot entirely rule out a modest increase or decrease in death due to bleeding with tranexamic acid, we can rule out the large mortality reduction suggested by the Cochrane review. Furthermore, tranexamic acid appears to increase the risk of venous thromboembolic events in patients with gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial. Our results highlight the unreliability of meta-analyses of small trials.

Methods {#cesec20}
=======

Study design and participants {#cesec30}
-----------------------------

The HALT-IT trial is an international, randomised, double blind (participants and trial staff), placebo-controlled trial done in 164 hospitals in 15 countries (UK, Pakistan, Nigeria, Egypt, Malaysia, Georgia, Romania, Nepal, Sudan, Saudi Arabia, Spain, Ireland, Albania, Papua New Guinea, and Australia).[@bib11] Patients were enrolled if they were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older) and if the responsible clinician was substantially uncertain whether to use tranexamic acid. The diagnosis of significant bleeding was clinical and significant was defined as a risk of bleeding to death and included patients with hypotension, tachycardia, or signs of shock, or those likely to need transfusion or urgent endoscopy or surgery.

Severe gastrointestinal bleeding is a frightening experience and blood loss can impact on a patient\'s mental and emotional state, impairing their decision making---the consent procedures considered this, as well as the need to treat urgently. If the patient was fully competent, written consent was sought. If capacity was impaired and a personal or professional representative was available, consent was sought from the representative. If neither were able to provide consent, it was waived and the patient was informed about the trial and consented for ongoing data collection as soon as possible afterwards. The trial was approved by the UK NRES Committee East of England (reference number 12/EE/0038), and by the national and local research ethics committees in all participating non-UK countries.

Randomisation and masking {#cesec40}
-------------------------

An independent statistician from Sealed Envelope (London, UK) generated randomisation numbers and these were given to Sharp Clinical Services UK (Crickhowell, UK), a Good Manufacturing Practice certified clinical trial service provider, to make treatment packs. When a patient was enrolled, the lowest numbered treatment pack was taken from a box of eight packs. Sharp Clinical Services was responsible for masking, which involved removing the manufacturer\'s label and replacing it with the clinical trial label and randomisation number. Apart from the randomisation number, the pack label text was identical for tranexamic acid and placebo. Patients, caregivers, and those assessing outcomes were masked to allocation. We checked the coding by testing each batch of ampoules with high-performance liquid chromatography to determine the contents. Block randomisation was used but randomisation was not stratified.

Procedures {#cesec50}
----------

Eligible patients were randomly assigned to get tranexamic acid or placebo as soon as possible and treatment was started immediately. A loading dose of 1 g tranexamic acid or placebo (sodium chloride 0·9%) was added to a 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid or placebo added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h. Every patient was assigned a uniquely numbered treatment pack, which contained eight ampoules of tranexamic acid 500 mg or placebo, one 100 mL bag of 0·9% sodium chloride (to use with the loading dose), two sterile 10 mL syringes and needles, stickers with the trial details and randomisation number (for attaching to infusion bags, forms, and the medical records), and instructions. Pfizer, Sandwich, UK (PL 00057/0952) manufactured the tranexamic acid and Torbay and South Devon NHS Foundation Trust (MIA \[IMP\] 13079) manufactured the sodium chloride 0·9% placebo. We provided information for patients and representatives, consent forms, and data collection forms. Stickers, instructions, leaflets, and forms were in local languages.

Once randomly assigned, we collected outcome data even if the treatment was not given. Outcome data were collected at death, discharge from the randomising hospital, or 28 days after randomisation, whichever occurred first. Trial investigators and their institutions provided direct access to the source data for trial-related monitoring, audits, and regulatory inspections. Monitoring was done according to the Sponsor\'s Standard Operating Procedure and the trial protocol. Formal inspections were carried out by the relevant Regulatory Agencies including the UK Medicines and Healthcare products Regulatory Agency, Irish Health Products Regulatory Authority, and Nigeria\'s National Agency for Food and Drug Administration and Control. Adherence to allocation sequence was monitored throughout the trial and any out of sequence pack use was automatically flagged in the trial database and the investigators were retrained.

Outcomes {#cesec60}
--------

The primary outcome was death due to bleeding within 5 days of randomisation. Cause of death was assigned by local principal investigators who provided a narrative of events leading to death. These were reviewed by the chief investigator (masked to treatment allocation) and queried if more information was needed to confirm whether death was due to bleeding or another cause. Secondary outcomes were death due to bleeding within 24 h and within 28 days of randomisation, all-cause and cause-specific mortality at 28 days, rebleeding within 24 h, within 5 days, and within 28 days of randomisation, surgery or radiological intervention, blood product transfusion, thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction), seizures, other complications (including other significant cardiac event, sepsis, pneumonia, respiratory failure, renal failure, liver failure), days in an intensive care unit, and functional status. The diagnosis of rebleeding was made by the clinician based on established criteria. A diagnosis of thromboembolic events was made using strict definitions and diagnostic criteria, including a clinical assessment, diagnostic imaging, biomarker tests, and post-mortem examination. Seizures were diagnosed by clinical assessment. Functional status was measured with the Katz Index of Independence in Activities of Daily Living either at hospital discharge or in-hospital at 28 days.

Statistical analysis {#cesec70}
--------------------

The sample size calculation was initially based on all-cause mortality as the primary outcome since we expected that most deaths would be due to bleeding.[@bib11] However, while the trial was underway, we observed that over half of all deaths were due to non-bleeding causes. Accumulating evidence from other large trials of tranexamic acid showed no apparent effect on non-bleeding deaths.[@bib12] Furthermore, patients received tranexamic acid (or placebo) only for their initial bleed and because tranexamic acid has a short half-life (approximately 2 h), it will be largely eliminated within 2 days. As such, we did not expect tranexamic acid to reduce deaths from rebleeding episodes many weeks after randomisation. The primary outcome was therefore changed to death due to bleeding within 5 days of randomisation on Nov 21, 2018. Based on the amended primary outcome, assuming a risk of death due to bleeding of 4%, a study with 12 000 patients has about 85% power (two-sided α of 5%) to detect a clinically important 25% relative reduction in death due to bleeding from 4% to 3%.

We published the statistical analysis plan before unblinding.[@bib13] The plan gave our reasons for amending the primary outcome measure and for increasing the sample size. The main analyses compared those allocated tranexamic acid with those allocated to placebo on a modified intention-to-treat basis, excluding patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. We present effect estimates (RRs) with a measure of precision (95% CI). The safety of participants was overseen by an independent data monitoring committee, which reviewed four non-masked interim analyses. We planned to report four subgroup analyses to examine the effects of tranexamic acid on the primary outcome stratified by the following baseline characteristics: time to treatment (≤3 h, \>3 h), site of bleeding (upper *vs* lower gastrointestinal), suspected variceal bleeding and comorbid liver disease compared with other or unknown causes of bleeding, and by clinical Rockall score. We modelled an interaction between the treatment effect and time to treatment with time to treatment as a continuous variable. We did post-hoc subgroup analyses to examine the effects of tranexamic acid on the primary outcome stratified by World Bank country income level (high *vs* low and middle income), anticoagulant use, and systolic blood pressure.

This trial was registered with Current Controlled Trials, ISRCTN11225767, and [ClinicalTrials.gov](http://ClinicalTrials.gov){#interrefs30}, [NCT01658124](NCT01658124){#interrefs40}.

Role of the funding source {#cesec80}
--------------------------

The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#cesec90}
=======

We enrolled the first patient on July 4, 2013, and the last on June 21, 2019. We stopped recruiting when the planned sample size was reached. When the decision to refine the primary outcome was made in Nov 21, 2018, we had recruited 10 190 patients. This decision was made blind to the accumulating trial data. 12 009 patients were enrolled and randomly assigned to receive either tranexamic acid (n=5994, 49·9%) or matching placebo (n=6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment ([figure 1](#fig1){ref-type="fig"}). 29 patients (11 in the tranexamic acid group and 18 in the placebo group) withdrew consent after randomisation, but of those, 12 (five in the tranexamic acid group and seven in the placebo group) agreed to provide outcome data or had outcome data collected as part of adverse event reporting. We obtained primary outcome data for all but three patients in the tranexamic acid group. There were 14 protocol violations (seven in the tranexamic acid group and seven in the placebo group), 11 patients did not meet the inclusion criteria (ten received tranexamic acid before randomisation \[six in the tranexamic acid group and four in the placebo group\], one in the placebo group was younger than 16 years), and there were three consent protocol violations (one in the tranexamic acid group and two in the placebo group). A total of 28 patients were unmasked to treatment (17 patients because the hospital team wanted to administer tranexamic acid, six because of adverse events, three because of clinical concerns, and two as part of post-mortem investigations \[13 in the tranexamic acid group and 15 in the placebo group\]). 52 patients received neither dose of the allocated trial treatment (29 patients in the tranexamic acid group and 23 patients in the placebo group).Figure 1Trial profile

223 patients received antifibrinolytic drugs as part of their clinical care, outside of the trial protocol (105 patients in the tranexamic acid group and 118 patients in the placebo group).

Baseline characteristics were similar between groups ([table 1](#tbl1){ref-type="table"}). [Figure 2](#fig2){ref-type="fig"} shows the number of deaths and cause of death by days since randomisation. There were 1112 deaths. The median time to death was 55 h after randomisation (IQR 18·2--161·8).Table 1Baseline characteristics**Tranexamic acid (n=5994)Placebo(n=6015)Age at randomisation, years**Mean (SD)58·1 (17·0)58·1 (17·0)\<40791 (13%)779 (13%)40--592356 (39%)2333 (39%)60--792078 (35%)2130 (35%)≥80769 (13%)773 (13%)**Sex**Female2142 (36%)2124 (35%)Male3852 (64%)3891 (65%)**Time from onset to randomisation, h**Mean (SD)21·4 (36·4)22·5 (37·8)≤3960 (16%)975 (16%)\>3--≤81607 (27%)1551 (26%)\>83427 (57%)3488 (58%)Missing01 (\<1%)**Suspected location of bleeding**Lower674 (11%)654 (11%)Upper5320 (89%)5361 (89%)**Haematemesis**Yes4285 (72%)4240 (71%)No1709 (29%)1775 (30%)**Melaena or fresh blood per rectum**Yes4573 (76%)4626 (77%)No1421 (24%)1389 (23%)**Suspected variceal bleeding**Yes2694 (45%)2739 (46%)No3300 (55%)3276 (54%)**Suspected active bleeding**Yes5247 (88%)5226 (87%)No747 (12%)789 (13%)**Systolic blood pressure, mm Hg**≥905222 (87%)5216 (87%)76--89577 (10%)577 (10%)≤75181 (3%)201 (3%)Missing14 (\<1%)21 (\<1%)**Heart rate, beats per min**\<77812 (14%)756 (13%)77--911546 (26%)1644 (27%)92--1071760 (29%)1720 (29%)\>1071864 (31%)1885 (31%)Missing12 (\<1%)10 (\<1%)**Signs of shock**Yes2574 (43%)2648 (44%)No3420 (57%)3367 (56%)**Rockall score**1--21419 (24%)1395 (23%)3--42306 (38%)2332 (39%)5--72269 (38%)2288 (38%)**Taking anticoagulants**Yes528 (9%)500 (8%)No5422 (90%)5466 (91%)Unknown44 (1%)49 (1%)**Emergency admission**Yes5673 (95%)5687 (94%)No321 (5%)328 (6%)**Major comorbidities**Cardiovascular1108 (18%)1132 (19%)Respiratory337 (6%)324 (5%)Liver2432 (41%)2532 (42%)Renal325 (5%)310 (5%)Malignancy417 (7%)382 (6%)Other999 (17%)968 (16%)Any comorbidity4308 (72%)4329 (72%)[^2]Figure 2Mortality by days from randomisation

Death due to bleeding within 5 days of randomisation ([table 2](#tbl2){ref-type="table"}) occurred in 222 (3·7%) of 5956 patients in the tranexamic acid group and in 226 (3·8%) of 5981 patients in the placebo group (RR 0·99, 95% CI 0·82--1·18). Similar results were obtained after adjusting for baseline covariates (0·98, 0·82--1·17) and in a per-protocol analysis (0·94, 0·71--1·23). When the 223 patients who received open-label antifibrinolytics were removed from the analysis, the results were similar (0·97, 0·81--1·17). We examined the effect of tranexamic acid on death due to bleeding within 5 days of randomisation in prespecified subgroup analyses stratified by time to treatment (heterogeneity p=0·53), location of bleeding (p=0·34), cause of bleeding (p=0·94), and clinical Rockall score (p=0·32) but recorded no evidence of heterogeneity for these factors ([figure 3](#fig3){ref-type="fig"}). When time since bleeding onset was modelled as a continuous variable there was no evidence of an interaction (heterogeneity p=0·53).Table 2Effect of tranexamic acid on death due to bleeding and rebleeding**Tranexamic acid (n=5956)Placebo (n=5981)Risk ratio (95% CI)**Death due to bleeding within 24 h124 (2·1%)120 (2·0%)1*·*04 (0*·*81--1*·*33)Death due to bleeding within 5 days222 (3·7%)226 (3·8%)0·99 (0·82--1·18)Death due to bleeding within 28 days253 (4·2%)262 (4·4%)0*·*97 (0*·*82--1*·*15)Rebleeding within 24 h[\*](#tbl2fn1){ref-type="table-fn"}41 (0·7%)41 (0·7%)1*·*00 (0*·*65--1*·*55)Rebleeding within 5 days[\*](#tbl2fn1){ref-type="table-fn"}287 (4·8%)315 (5·3%)0*·*91 (0*·*78--1*·*07)Rebleeding within 28 days[\*](#tbl2fn1){ref-type="table-fn"}410 (6·8%)448 (7·5%)0*·*92 (0*·*81--1*·*05)[^3][^4]Figure 3Effect of tranexamic acid on death due to bleeding within 5 daysAnalysis stratified by time since bleeding onset, suspected bleed location, suspected variceal bleeding or comorbid liver disease, and Rockall score.

We examined the effect of tranexamic acid on death due to bleeding within 5 days of randomisation stratified by World Bank country income level (high-income *vs* low-income and middle-income), anticoagulant use and systolic blood pressure. These exploratory analyses were not prespecified. The relative risks did not appear to vary by country income, anticoagulant use, or systolic blood pressure ([appendix p 6](#sec1){ref-type="sec"}).

Death due to bleeding within 24 h of randomisation occurred in 124 (2·1%) patients in the tranexamic acid group and 120 (2·0%) patients in the placebo group (RR 1·04, 95% CI 0·81--1·33). Death due to bleeding within 28 days of randomisation occurred in 253 (4·2%) patients in the tranexamic acid group and 262 (4·4%) patients in the placebo group (0·97, 0·82--1·15). Death from all-causes within 28 days of randomisation occurred in 564 patients (9·5%) in the tranexamic acid group and in 548 patients (9·2%) in the placebo group (1·03, 0·92--1·16; [table 3](#tbl3){ref-type="table"}). The proportion of patients with rebleeding was similar in both groups at 24 h, 5 days, and 28 days after randomisation ([table 3](#tbl3){ref-type="table"}). The proportion of patients who had surgery, radiological intervention, and blood product transfusion was also similar in both groups ([table 4](#tbl4){ref-type="table"}).Table 3Effect of tranexamic acid on all-cause death**Tranexamic acid (n=5956)Placebo(n=5981)Risk ratio(95% CI)**Bleeding253 (4*·2%*)262 (4*·4%*)0*·*97 (0*·*82--1*·*15)Thromboembolic event26 (0·4%)17 (0·3%)1*·*54 (0*·*83--2*·*83)Organ failure109 (1·8%)114 (1·9%)0*·*96 (0*·*74--1*·*25)Pneumonia57 (1*·0%*)42 (0·7%)1*·*36 (0*·*92--2*·*03)Sepsis33 (0·6%)49 (0·8%)0*·*68 (0*·*44--1*·*05)Malignancy65 (1*·1%*)40 (0·7%)1*·*63 (1*·*10--2*·*42)Other21 (0·4%)24 (0·4%)0*·*88 (0*·*49--1*·*58)All cause564 (9·5%)548 (9*·2%*)1*·*03 (0*·*92--1*·*16)[^5]Table 4Effect of tranexamic acid on the need for surgical, endoscopic, and radiological interventions or blood product transfusion**Tranexamic acidPlaceboOutcomesInterventions**Diagnostic endoscopy4781/5953 (80·3%)4729/5978 (79*·1%*)1*·*02 (1*·*00 to 1*·*03)Therapeutic endoscopy2542/5952 (42·7%)2658/5978 (44.5%)0*·*96 (0*·*92 to 1*·*00)Diagnostic radiological procedure1704/5953 (28·6%)1744/5978 (29*·2%*)0*·*98 (0*·*93 to 1*·*04)Therapeutic radiological procedure74/5953 (1·2%)89/5978(1·5%)0*·*83 (0*·*61 to 1*·*13)Surgical intervention146/5953 (2·5%)158/5978 (2·6%)0*·*93 (0*·*74 to 1*·*16)Any surgical, endoscopic, or radiological intervention5216/5956 (87·6%)5236/5981 (87·5%)1*·*00 (0*·*99 to 1*·*01)Any transfusion4076/5951 (68·5%)4129/5978 (69*·1%*)0*·*99 (0*·*97 to 1*·*02)Whole blood or red cells3984/4076 (97·7%)4018/4129 (97*·3%*)1*·*00 (1*·*00 to 1*·*01)Frozen plasma910/4076 (22·3%)993/4129 (24*·0%*)0*·*93 (0*·*86 to 1*·*00)Any platelets219/4076 (5·4%)255/4129 (6*·2%*)0*·*87 (0*·*73 to 1*·*04)**Blood product transfusions**Units of whole blood or red cells2*·*8 (2*·*4)2*·*9 (2*·*7)−0·06 (0*·*05 to −0*·*18)Units of frozen plasma0*·*9 (2*·*4)1*·*0 (2*·*6)−0*·*05 (−0*·*01 to −0*·*23)Units of any platelets0*·*2 (0*·*9)0*·*2 (1*·*0)−0*·*02 (0*·*02 to −0*·*06)[^6]

The risk of fatal or non-fatal thromboembolic events and arterial thromboembolic events (myocardial infarction or stroke) was similar in the tranexamic acid group and the placebo group ([table 5](#tbl5){ref-type="table"}). The risk of venous thromboembolic events (deep vein thrombosis or pulmonary embolus) was higher in the tranexamic group than in the placebo group ([table 5](#tbl5){ref-type="table"}) and similar risk was observed after excluding patients who did not receive the maintenance dose (42 events with tranexamic acid *vs* 20 with placebo); RR 2·11, 95% CI 1·24--3·59). In an exploratory subgroup analysis, the risk of venous thromboembolic events was higher in patients with suspected variceal bleeding or liver disease (14 *vs* two events; 7·26, 1·65--31·90) than in patients with other causes of bleeding (34 *vs* 24 events; 1·38, 0·82--2·32; p=0·035 for heterogeneity). The risk of renal, hepatic, and respiratory failure, cardiac events, sepsis, and pneumonia was similar in tranexamic acid and placebo treated patients ([table 5](#tbl5){ref-type="table"}). Seizures occurred in 38 patients on tranexamic acid and 22 on placebo (0·6% *vs* 0·4%; 1·73, 1·03--2·93; [table 5](#tbl5){ref-type="table"}), and after excluding patients who did not receive the maintenance dose the corresponding numbers were 33 versus 17 events (1·95, 1·09--3·50).Table 5Complications and self-care capacity in study groups**Tranexamic acidPlaceboOutcomesComplications**Any thromboembolic event86/5952 (1·4%)72/5977 (1·2%)1*·*20 (0*·*88 to 1*·*64)Venous events (deep vein thrombosis, pulmonary embolism)48/5952 (0·8%)26/5977 (0·4%)1*·*85 (1*·*15 to 2*·*98)Deep vein thrombosis23/5952 (0·4%)12/5977 (0·2%)1*·*92 (0*·*96 to 3*·*86)Pulmonary embolism28/5952 (0·5%)16/5977 (0·3%)1*·*76 (0*·*95 to 3*·*24)Arterial events (myocardial infarction, stroke)42/5952 (0·7%)46/5977 (0·8%)0*·*92 (0*·*60 to 1*·*39)Myocardial infarction24/5952 (0·4%)28/5977 (0·5%)0*·*86 (0*·*50 to 1*·*48)Stroke19/5952 (0·3%)18/5977 (0·3%)1*·*06 (0*·*56 to 2*·*02)Renal failure142/5951 (2·4%)157/5978 (2·6%)0*·*91 (0*·*73 to 1*·*14)Liver failure196/5952 (3·3%)184/5977 (3·1%)1*·*07 (0*·*88 to 1*·*30)Respiratory failure105/5952 (1·8%)131/5978 (2·2%)0*·*81 (0*·*62 to 1*·*04)Cardiac event100/5952 (1·7%)89/5977 (1·5%)1*·*13 (0*·*85 to 1*·*50)Sepsis210/5952 (3·5%)216/5977 (3·6%)0*·*98 (0*·*81 to 1*·*18)Pneumonia193/5952 (3·2%)174/5978 (2·9%)1*·*11 (0*·*91 to 1*·*36)Seizure38/5952 (0·6%)22/5977 (0·4%)1*·*73 (1*·*03 to 2*·*93)**Self-care capacity**Days in ICU0*·*4 (1*·*8)0*·*4 (2*·*0)−0*·*06 (0*·*01 to −0*·*13)Katz score5*·*5 (1*·*5)5*·*5 (1*·*4)−0*·*03 (0*·*02 to −0*·*09)[^7]

The mean number of days spent in intensive care was similar in both groups ([table 5](#tbl5){ref-type="table"}). The mean score on the Katz Index of Independence in Activities of Daily Living was also similar in both groups ([table 5](#tbl5){ref-type="table"}).

Discussion {#cesec100}
==========

In this trial, tranexamic acid did not reduce death from gastrointestinal bleeding but was associated with an increased risk of venous thromboembolic events and seizures. The proportion of patients with rebleeding was similar in the tranexamic acid and placebo groups.

The randomisation method ensured that participating clinicians had no foreknowledge of the treatment allocation and placebo control ensured outcome assessment was blind to treatment group. The inclusion criteria were clinical, reflecting the full range of gastrointestinal bleeding presentations that doctors face in day-to-day practice. Baseline prognostic factors were well balanced and almost all randomly assigned patients were followed up. The primary outcome was death due to bleeding within 5 days of randomisation. Our scientific reasons for pre-specifying death due to bleeding as the primary outcome in the statistical analysis plan are presented in detail elsewhere.[@bib12] Although some misclassification of cause of death is possible, the assessment was masked to the treatment group. However, because there was no evidence of a treatment effect for the prespecified primary endpoint (death due to bleeding at 5 days) or for death from any cause at 28 days, the choice of endpoint does not influence the interpretation of the results. Misclassification might also have affected our subgroup analyses because at the time of recruitment the site and cause of bleeding cannot be known with certainty. Our use of the pre-endoscopy Rockall score might have misclassified baseline risk.[@bib14] To minimise the risk of false positives, we used strict criteria to diagnose thromboembolic events, including a positive result on imaging (eg, ultrasound) or at post-mortem examination. Although using this criteria might have led to some under reporting, because the diagnostic tests have high specificity, the relative risk estimates should be unbiased. Although some patients received antifibrinolytics outside of the protocol, the treatment effect was the same when these patients were excluded. Although this is one of the largest randomised trials in gastrointestinal bleeding, we cannot rule out a modest increase or decrease in death due to bleeding with tranexamic acid. That said, we can rule out the large mortality reduction suggested by the Cochrane systematic review and meta-analysis of previous small trials.[@bib9]

Administration of tranexamic acid within 3 h of bleeding onset reduces death due to bleeding in trauma and post-partum haemorrhage without increasing the risk of thromboembolic events. In these bleeding scenarios, the timing of onset is easy to determine, most patients present early, and there are well documented changes in fibrinolysis that provide a biological rationale for tranexamic acid treatment.[@bib15], [@bib16] However, in gastrointestinal bleeding it is difficult to determine the time of bleeding onset, presentation is often delayed (over 80% of patients presented more than 3 h after bleeding onset), and the contribution of increased fibrinolysis to bleeding is less clear.

Almost half of the patients included in our trial had suspected variceal bleeding due to liver disease and because these patients had a greater risk of death, they accounted for nearly three-quarters of deaths. Recent research shows that acutely ill patients with cirrhosis have a mixed fibrinolytic phenotype.[@bib17] Some have increased fibrinolysis, but others have profound hypofibrinolysis. The prevalence of hypofibrinolysis appears to be greatest in the most critically ill patients. Using the same clot lysis assay, reduced fibrinolysis has been shown to be associated with a small increased risk of venous thrombosis.[@bib18] In our trial, the increased risk of venous thromboembolic events with tranexamic acid appeared to be more marked in patients with liver disease, although this was an exploratory subgroup analysis and there was no strong evidence for heterogeneity. Nevertheless, reduced fibrinolysis in patients with liver disease might explain the absence of reduction in bleeding deaths with tranexamic acid and the increased risk of venous thromboembolic events.

The dose of tranexamic acid used in this trial was higher and the duration of treatment was longer (4 g over 24 h) than in randomised trials of tranexamic acid in trauma (2 g over 8 h) or post-partum haemorrhage (1 g bolus with a repeat 1 g dose if bleeding continued), which did not record any increase in adverse events with tranexamic acid. Patients with gastrointestinal bleeding often rebleed after initial haemostasis, particularly within the first 24 h. Because tranexamic acid has a short half-life, we used a longer treatment duration to cover this high-risk period. Furthermore, previous trials in gastrointestinal bleeding that appeared to show a large mortality reduction with tranexamic acid used a high dose and a longer duration of treatment than trials in trauma and post-partum haemorrhage.[@bib9] The longer duration of tranexamic acid treatment in this trial might explain the increased risk of venous thromboembolic events and the higher dose could possibly explain the increased risk of seizures.[@bib19]

In summary, we found no evidence that tranexamic acid decreases the risk of death in patients with gastrointestinal bleeding. Our results caution against a uniform approach to the management of patients with major haemorrhage and highlight the need for randomised trials targeted at specific pathophysiological processes. Because gastrointestinal bleeding is a licensed indication for tranexamic acid, our results could have regulatory implications. Although this trial can rule out the large mortality reduction suggested by the meta-analysis of previous small trials, it cannot rule out more modest treatment effects. Because tranexamic acid reduces bleeding deaths in patients with traumatic and postpartum haemorrhage, individual patient data meta-analyses should assess the strength of the evidence that the effectiveness and safety of tranexamic acid varies by the site and cause of bleeding.

Correspondence to: Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London WC1 E7HT, UK <haltit@lshtm.ac.uk>
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[^1]: Members listed at end of paper

[^2]: Data are n (%) or mean (SD).

[^3]: Data are n (%) and risk ratio (95% CI). Death or rebleeding in hospital during follow-up.

[^4]: Excludes 13 patients missing data on rebleed status or rebleed date.

[^5]: Data are n (%) and risk ratio (95% CI). Death in hospital during follow-up.

[^6]: Data for interventions are n/N (%) and risk ratio (95% CI); data for blood product transfusions are mean (SD) and difference in means (95% CI).

[^7]: Data for complications are n/N (%) and risk ratio (95% CI); data for self-care capacity are mean (SD) and difference in means (95% CI). Thromboembolic events and complications are not mutually exclusive. ICU=intensive care unit.
